Dr Diekman, Ph.D. is a founder and Managing Partner of 5AM Ventures. Prior to founding 5AM, Dr. Diekman was a founder and Managing Director of Bay City Capital, a life sciences investment firm. Previously, Dr. Diekman was Chairman and CEO of Affymetrix, Inc, where he still serves as a Director. Dr. Diekman currently serves as Board Chairman of Ambrx and Phenomix as well as on the Boards of Directors of Igenica, Ingenuity Systems, Marcadia, PhaseRx and Wildcat Discovery. Dr. Diekman was the Vice-Chairman of Singapore's Life Science Fund, Bio*One Capital and he currently serves as advisor. He was recently named a Trustee of Princeton University and is also former Trustee of The California Institute of Technology and The Scripps Research Institute, where he served as Chairman. Dr. Diekman holds a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University.